Compare CVS Health Corp (CVS) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Wahed FTSE USA Shariah ETF — how do they compare? CVS Health Corp trades at $86.27 (market cap $112.29B), while Wahed FTSE USA Shariah ETF trades at $75.86 (market cap $1.00B). The key difference: CVS Health Corp is far larger — about 112.3× Wahed FTSE USA Shariah ETF's market cap, and CVS Health Corp pays a 3.03% dividend while Wahed FTSE USA Shariah ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Wahed FTSE USA Shariah ETF for 65 Days on average.
| CVS | HLAL | |
|---|---|---|
Market Cap | $112.29B | $1.00B |
Volume | 7,763,676 | 51,137 |
Sector | Health | Sector/Thematic |
52-Week High | $110.60 | $76.54 |
52-Week Low | $70.08 | $57.46 |
Typical Hold Time | 83 Days | 65 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
HLAL trades at $76.44, down 0.13% with limited daily movement. The technical picture shows bullish momentum with strong moving average support, though RSI levels above 70 indicate potential overbought conditions. Support and resistance cluster tightly around $76-77, suggesting a critical price zone. Recent corporate actions include a $0.10 dividend scheduled for September 2026.
The stock faces valuation uncertainty with key financial ratios unavailable, requiring deeper fundamental analysis. Technical strength supports near-term upside, but overbought signals and lack of current financial metrics present investment challenges. Investors need updated earnings reports and analyst coverage to assess the company's financial health and growth prospects accurately.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
